Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...David Mitchell, founder of Patients for Affordable Drugs, a US campaign group, said that for some companies, such as Boston-based biotech Moderna, the government seemed to be paying for everything....
...Brunswick Group hired former Pfizer China government affairs vice-president Xi Qing as a partner in Asia....
...It did not take long for Pfizer to perform a U-turn....
...David Mitchell, a campaigner from Patients For Affordable Drugs, said it made little sense to focus only on “outliers” such as Shkreli given that successive years of above-inflation increases on thousands...
...US court told PwC cut corners in Colonial audit Control+C, Control+V....
...FastFT has corporate news from Mitchells & Butlers, Drax, De La Rue, John Menzies and Shaftesbury....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...However, in drug discovery, the timescales and cost are daunting, says Andrew Mitchell, chief executive of North East Finance, which oversees seven funds in that region....
...“Pfizer China also created various ‘point programmes’ under which government doctors could accumulate points based on the number of Pfizer prescriptions they wrote....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...In December 2002, they made a bolder move, spending $4.2bn to buy a gum company called Adams that had been put up for sale by the US drugs company Pfizer....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...Kevin Mitchell, of the Business Travel Coalition, said: “This is a top priority for many companies because it affects their bottom line.”...
...Kindler, Chairman and CEO, Pfizer Inc., USA Klaus Kleinfeld, President and CEO, Siemens AG, Germany Mustafa V....
...“We maintain our view that a price up to 625p would be acceptable for Eon to pay,” said Ian Mitchell, an analyst at JPMorgan....
...He was born in 1954, the year, as he points out, of the famous Brown v Board of Education case which paved the way for US desegregation....
International Edition